Endothelin antagonists are drug candidates that acts against
endothelin receptors and generate pharmacological actions such as blocking the
vasoconstriction and mediate vasodilatation. Endothelin-1 is a peptide which is
comprised of 21 amino acids and formed by vascular endothelium. The biological
molecule is a potent vasoconstrictor that binds to endothelin receptors A and
B. This further leads to the activation of IP3 DA pathway that causes efflux of
calcium ions from the endoplasmic reticulum and produce vasoconstriction in the
smooth muscles.
AbbVie Inc. is in the process of developing ABT-627 as an
endothelin receptor antagonist for the treatment of diabetic nephropathy in
type 2 diabetes. Idorsia Pharmaceuticals Ltd. is developing ACT-132577 as an
endothelin receptor antagonist for the treatment of resistant hypertension.
Moreover, Retrophin Inc. is also developing sparsentan as an endothelin
receptor antagonist for the treatment of focal segmental glomerulosclerosis.
Ligand Pharmaceuticals Inc., and ENB Therapeutics LLC are some other companies
having pipeline of endothelin receptor antagonist.
Download Free PDF Sample Copy:
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and
development activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
